CHROMENONE ANALOGUES AS SIRTUIN MODULATORS Russian patent published in 2014 - IPC C07D311/22 C07D405/12 C07D405/14 C07D417/12 C07D417/14 C07D413/12 A61K31/353 A61P3/10 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel chromenone derivatives of formula II or its pharmaceutically acceptable salts, where each R²⁰ is hydrogen; R¹¹ is selected from phenyl and 5-6 member saturated or aromatic heterocycle, including one or two heteroatoms, selected from N, O or S, where R¹¹ is optionally substituted with one-two substituents, independently selected from C₁-C₄alkyl, =O, -O-R¹³, -(C₁-C₄alkyl)-N(R¹³)(R¹³), -N(R¹³)(R¹³), where each R¹³ is independently selected from hydrogen and -C₁-C₄alkyl; or two R¹³ together with nitrogen atom, to which they are bound, form 5-6-member saturated heterocycle, optionally including one additional O, where, when R¹³ is alkyl, alkyl is optionally substituted with one or more substituents, selected from -OH, fluorine, and, when two R¹³ together with nitrogen atom, to which they are bound, form 6-member saturated heterocycle, saturated heterocycle is optionally substituted on each carbon atom with -C₁-C₄alkyl; R¹² is selected from phenyl and pyridyl, where R¹² is optionally substituted with one or more substituents, independently selected from halogen, C₁-C₄alkyl, C₁-C₂ fluorine-substituted alkyl, -O-R¹³, -S(O)₂-R¹³, -(C₁-C₄alkyl)-N(R¹³)(R¹³), -N(R¹³)(R¹³); R¹⁴ is selected from hydrogen; and X¹ is selected from -NH-C(=O)-†, -C(=O)-NH-†, - -S(=O)₂-NH-†, where † stands for place, where X¹ is bound with R¹¹; and, when R¹⁴ is H; R¹²is phenyl; and X¹ is - C(=O)-NH-†, then R¹¹ is not 1H-pyrazol-3-yl, possessing stimulating activity.

EFFECT: invention relates to pharmaceutical composition based on said compounds, method of treating subject, suffering from or having resistance to insulin, metabolic syndrome or diabetes, as well as to method of increasing sensitivity to insulin.

16 cl, 1 tbl, 24 ex